Born: January 1963
Education: PhD in Microbiology from Freie Universität Berlin, Germany
Thomas Schäfer joined Chr. Hansen in November 2017 as Executive Vice President & Chief Scientific Officer bringing with him 23 years of experience from Novozymes. As a German national, Thomas Schäfer’s professional career started in 1994 where he joined the enzyme division of Novo Nordisk (in 2000 split into Novozymes) in Microbial Screening as a PostDoc.
Throughout his years in Novozymes, he has held various senior positions primarily within R&D and Business Development. In 2013 Thomas Schäfer played a key role in making the BioAg Alliance with Monsanto a reality. This led to three years of expatriation in North Carolina, US, where he established Novozymes’ BioAg Application Research unit in RTP.
Mr. Schäfer’s experience spans across both bacteria and enzymes under the umbrella of which he is further the co-inventor on a number of patents as well as publisher of several scientific papers and publications with WWF, WEF and the German Bioeconomy council.
Mr. Schäfer serves as a member of the Board of Directors of the BioInnovation Institute established by the Novo Nordisk Foundation and as a member of the Advisory Board for DTU Bioengineering. Further Mr. Schäfter serves as a member of the Board of Directors of Bacthera AG (Switzerland) and member of the Board of Directors of Bacthera Denmark A/S (Denmark).